安进Amgen Inc. (AMGN) 2010年年度报告「NASDAQ」.pdf

1、Amgen 2010 Annual Reportand Financial Summary3/9/11 12:32 PM3/9/11 12:32 PMAbout AmgenAmgen discovers,develops,manufactures,and delivers innovative human therapeutics.A biotechnology pioneer since 1980,Amgen was one of the fi rst companies to realize the new sciences promise by bringing safe,effecti

2、ve medicines from lab to manufacturing plant to patient.Amgen therapeutics have changed the practice of medicine,helping millions of people around the world in the fi ght against cancer,kidney disease,rheumatoid arthritis,bone disease,and other serious illnesses.With a deep and broad pipeline of pot

3、ential new medicines,Amgen remains committed to advancing science to dramatically improve peoples lives.Amgen MissionTo serve patientsAmgen ValuesBe science-basedCompete intensely and winCreate value for patients,staff,and stockholdersBe ethicalTrust and respect each otherEnsure qualityWork in teams

4、Collaborate,communicate,and be accountable28822_Cov.indd 228822_Cov.indd 2Dear Stockholders,2010 was a year of challenges met and promises delivered for Amgens patients,stockholders,and staff.We delivered an important,innovative bone health therapy,denosumab,in the form of two novel medicines:Prolia

5、,approved in Europe,the United States,and several other countries for postmenopausal osteoporosis,and XGEVA,approved in the United States for the prevention of skeletal-related events in patients with bone metastases from solid tumors.We grew revenues 3 percent,adjusted earnings per share*6 percent,

6、and generated nearly$6 billion in operating cash fl ow,despite continuing global economic turmoil and a$200 million adverse impact to revenues from U.S.healthcare reform and reimbursement headwinds.In sum,it was a superb operational year.Developing Denosumab:Amgen at Its BestThe story of the develop